Ferner R E, Simpson J M, Rawlins M D
Br Med J (Clin Res Ed). 1987 May 2;294(6580):1119-20. doi: 10.1136/bmj.294.6580.1119.
Inhibitors of angiotensin converting enzyme may cause angio-oedema. To see if this might be due to potentiation of the tissue effects of bradykinin the thickness of weals raised by intradermal injection of saline or 1, 3, or 10 micrograms bradykinin was measured before and three times after single doses of captopril, enalapril, or placebo. The mean thickness increased with increasing doses of bradykinin. It did not change with time after the administration of placebo or captopril but increased from 0.61 mm before enalapril to 1.12 mm two and a half hours and 1.06 mm five hours after enalapril was given. Five subjects flushed when given bradykinin after captopril and four after enalapril, but none flushed when given bradykinin after placebo. It is concluded that angiotensin converting enzyme inhibitors potentiate the effects of intradermal bradykinin in vivo and that this may partially explain why they cause angio-oedema in susceptible patients.
血管紧张素转换酶抑制剂可能会引起血管性水肿。为了探究这是否可能是由于缓激肽的组织效应增强所致,在单次给予卡托普利、依那普利或安慰剂之前及之后三次,测量皮内注射生理盐水或1、3或10微克缓激肽所引起的风团厚度。风团的平均厚度随缓激肽剂量的增加而增加。给予安慰剂或卡托普利后,其厚度随时间未发生变化,但给予依那普利后,厚度从给药前的0.61毫米增加到给药后两小时半的1.12毫米以及五小时后的1.06毫米。五名受试者在服用卡托普利后给予缓激肽时出现脸红,四名受试者在服用依那普利后给予缓激肽时出现脸红,但服用安慰剂后给予缓激肽时无人脸红。结论是血管紧张素转换酶抑制剂在体内增强了皮内缓激肽的作用,这可能部分解释了它们为何会在易感患者中引起血管性水肿。